The tweet was deleted by the author.
But we saved everything 🙂.
Anika Therapeutics has introduced Hyaff, an esterified form of hyaluronic acid engineered to last longer in the body.
This extended longevity enables the development of implantable scaffolds that support regenerative medicine and tendon repair, potentially offering longer-lasting clinical benefits for patients. By modifying natural hyaluronic acid, Anika Therapeutics aims to address the challenges of rapid breakdown in biological environments, paving the way for more sustainable and effective therapeutic solutions. Hyaff represents a significant step in the evolution of regenerative technologies, as companies race to develop advanced biomaterials for complex clinical needs.
Anika Therapeutics has previously introduced Hyalofast, a single-stage scaffold for cartilage repair, which also uses Hyaff hyaluronic acid technology. The company has also presented Cingal as the only approved hyaluronic acid and corticosteroid combination therapy for osteoarthritis pain. Both products reflect Anika's ongoing efforts to expand its regenerative medicine and pain management portfolio.